MyoKardia
MyoKardia was a clinical-stage biopharmaceutical company that developed cardiac myosin modulator therapies for rare cardiovascular diseases, including the FDA-approved mavacamten for hypertrophic cardiomyopathy. The company was acquired by Bristol Myers Squibb in 2020 for approximately $13.1 billion and now operates as a wholly-owned subsidiary.
- Company typePrivate
- Founded2015
- HeadquartersBrisbane, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What MyoKardia does
MyoKardia was a clinical-stage biopharmaceutical company founded in 2012 (incorporated as an independent biotech in 2015) and based in South San Francisco, California, that developed targeted therapies for rare cardiovascular diseases. Its proprietary platform centered on cardiac myosin modulators — small molecules designed to correct the underlying biophysical mechanisms of heart muscle contraction — applied to genetic conditions where prior therapies only managed symptoms. The company originated mavacamten, a first-in-class cardiac myosin inhibitor that received FDA approval in 2021 for hypertrophic cardiomyopathy (HCM), a condition affecting roughly 1 in 500 people in the US. Its pipeline additionally included danicamtiv (a cardiac myosin activator in Phase 2b/3 for genetically driven dilated cardiomyopathy), ataciguat (licensed from Sanofi/Mayo Clinic for calcific aortic valve stenosis), and tonlamarsen (licensed from Ionis Pharmaceuticals for acute severe hypertension).
The company's revenue model was that of a traditional development-stage biotech: it did not generate commercial product revenue, instead funding operations through venture capital (approximately $98 million raised across rounds in 2012-2017) and capturing value through eventual commercialization or M&A. In November 2020, Bristol Myers Squibb acquired MyoKardia for approximately $13.1 billion, providing BMS with full rights to mavacamten (now marketed as Camzyos) and the broader cardiac myosin pipeline. Post-acquisition, MyoKardia operates as a wholly-owned subsidiary of BMS with its assets reported within BMS's cardiovascular franchise. Several former MyoKardia founders and executives subsequently launched Kardigan in 2023 to advance late-stage cardiovascular programs outside of BMS.
MyoKardia firmographics
Firmographics- Name
- MyoKardia
- Website
- https://myokardia.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Short description
- MyoKardia was a clinical-stage biopharmaceutical company that developed cardiac myosin modulator therapies for rare cardiovascular diseases, including the FDA-approved mavacamten for hypertrophic cardiomyopathy. The company was acquired by Bristol Myers Squibb in 2020 for approximately $13.1 billion and now operates as a wholly-owned subsidiary.
- Ownership category
- akta.pro rank
MyoKardia industry classification
Industry- Product category
- Cardiovascular Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)
- akta.pro secondary industries
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where MyoKardia is headquartered
LocationHeadquarters
- HQ city
- Brisbane
- HQ country
- United States
- HQ region
- North America
Markets served
MyoKardia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Drug development and commercialization: Traditional biotech revenue model focused on developing and commercializing novel cardiovascular medicines. The company developed proprietary compounds through clinical trials toward regulatory approval and market launch.
MyoKardia product offering
Product offeringCore offering
MyoKardia developed targeted small-molecule therapies for rare cardiovascular diseases based on proprietary cardiac myosin modulation technology. Its lead asset, mavacamten (marketed as Camzyos), received FDA approval for hypertrophic cardiomyopathy, while additional programs included danicamtiv (dilated cardiomyopathy), ataciguat (calcific aortic valve stenosis), and tonlamarsen (acute severe hypertension). The company originated the cardiac myosin activator drug class and advanced candidates through clinical development toward regulatory approval.
Product overview
MyoKardia was a cardiovascular biotech company focused on developing targeted therapies for heart diseases. The company originated cardiac myosin modulators including danicamtiv (a cardiac myosin activator in Phase 2b/3 for dilated cardiomyopathy) and mavacamten (an FDA-approved treatment for hypertrophic cardiomyopathy). MyoKardia was acquired by Bristol-Myers Squibb in 2020. Veterans of MyoKardia subsequently founded Kardigan to advance three late-stage cardiovascular programs: danicamtiv, ataciguat (licensed from Sanofi and Mayo Clinic for calcific aortic valve stenosis), and tonlamarsen (licensed from Ionis Pharmaceuticals for acute severe hypertension).
Differentiator
Problem solved
Functional benefit
Products and services
- Mavacamten (Camzyos)
- Danicamtiv
- Ataciguat
- Tonlamarsen
Quantifiable outcome
- Mavacamten (Camzyos) approved by FDA for hypertrophic cardiomyopathy treatment
Companies that use MyoKardia
Customer profileSegments1 record
Ideal customer profiles1 record
MyoKardia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
MyoKardia partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights4 records
MyoKardia competitors and assessment
Company assessmentDirect peers
- Cytokinetics: Cardiovascular-focused biopharma developing cardiac myosin modulators (e.g., omecamtiv mecarbil, aficamten) for HCM and heart failure. Most directly comparable to MyoKardia given shared cardiac myosin mechanism and overlapping cardiovascular indications.
- Tenaya Therapeutics: Clinical-stage genetic medicines company focused on heart disease, with programs in HCM and DCM. Comparable to MyoKardia through shared focus on genetically-driven cardiomyopathies and rare cardiovascular indications.
- Edgewise Therapeutics: Clinical-stage biopharma developing precision medicines for cardiac and muscle diseases, including programs targeting cardiac myosin and HCM. Directly comparable to MyoKardia in mechanism and disease focus.
- Stealth BioTherapeutics: Clinical-stage biopharma developing therapies for rare cardiomyopathies and mitochondrial diseases. Comparable to MyoKardia through shared focus on rare cardiac indications with high unmet need.
Broad incumbents
- Bristol Myers Squibb: MyoKardia's parent company post-2020 acquisition; a global biopharmaceutical company with cardiovascular, oncology, immunology, hematology, and neuroscience franchises. Operates MyoKardia as a wholly-owned subsidiary within its cardiovascular business.
- Novartis: Global biopharmaceutical company with a substantial cardiovascular franchise (e.g., Entresto for heart failure). Broad incumbent competitor operating across multiple cardiovascular indications including HCM and heart failure.
- AstraZeneca: Global biopharmaceutical company with cardiovascular and rare disease franchises (including Alexion). Broad incumbent with overlapping capabilities in cardiology and rare cardiovascular therapeutics.
Emerging players
- Kardigan: Cardiovascular biopharma founded in 2023 by former MyoKardia executives and founders. Is advancing danicamtiv, ataciguat, and tonlamarsen — assets originated at MyoKardia — making it the most direct emerging spin-out competitor.
- Lexeo Therapeutics: Clinical-stage gene therapy company with a focus on cardiac genetic diseases, including DCM. Comparable to MyoKardia in targeting genetically-defined cardiovascular patient populations.
- Imbria Pharmaceuticals: Clinical-stage biopharma developing therapies that target cardiac metabolism for the treatment of cardiomyopathies and heart failure. Comparable to MyoKardia in mechanism-driven approach to cardiovascular disease.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
MyoKardia social profiles
Digital presenceMyoKardia financial estimates
Financial estimateRevenue estimate
Valuation estimate
MyoKardia leadership team
Management profileNumber of profiles
Profiles1 record
MyoKardia funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MyoKardia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MyoKardia
What does MyoKardia do?
MyoKardia developed targeted small-molecule therapies for rare cardiovascular diseases based on proprietary cardiac myosin modulation technology. Its lead asset, mavacamten (marketed as Camzyos), received FDA approval for hypertrophic cardiomyopathy, while additional programs included danicamtiv (dilated cardiomyopathy), ataciguat (calcific aortic valve stenosis), and tonlamarsen (acute severe hypertension). The company originated the cardiac myosin activator drug class and advanced candidates through clinical development toward regulatory approval.
Is MyoKardia a public or private company?
MyoKardia is a private company. It is classified as corporate owned and is currently acquired.
When was MyoKardia founded?
MyoKardia was founded in 2015. It employs 251 to 500 people.
Where is MyoKardia based?
MyoKardia is headquartered in Brisbane, United States, in the North America region.
How does MyoKardia make money?
One revenue line is on record: drug development and commercialization.
Who are MyoKardia's main competitors?
Direct peers on record are Cytokinetics, Tenaya Therapeutics, Edgewise Therapeutics and Stealth BioTherapeutics. Broad incumbents are Bristol Myers Squibb, Novartis and AstraZeneca. Emerging players are Kardigan, Lexeo Therapeutics and Imbria Pharmaceuticals.
Does MyoKardia have an API?
No public API is recorded for MyoKardia.
What industry is MyoKardia in?
MyoKardia's product category is Cardiovascular Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies, with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2833.